For Jazz Pharmaceuticals, Failure Is the New Winning

To U.S. oncologists who treat individuals with small cell lung cancer, lurbinectedin’s arrival was a big deal. The Food and Drug Administration permitted its sale in the United States under its accelerated approval program. Then the drug failed to meet the primary endpoint of its clinical trial’s Phase III.